Literature DB >> 22508443

Validation of the first quality-of-life measurement for patients with Huntington's disease: the Huntington Quality of Life Instrument.

Emilie Clay1, Annunziata De Nicola, Julie Dorey, Ferdinando Squitieri, Samuel Aballéa, Tiziana Martino, Joakim Tedroff, Daniel Zielonka, Pascal Auquier, Christophe Verny, Mondher Toumi.   

Abstract

Health-related quality-of-life instruments are critical for assessing disease burdens. Generic tools allow comparison between diseases but do not discriminate between disease severities. Specific tools also tend to be more sensitive. No specific tool is available to assess quality of life in patients with Huntington's disease (HD). In the context of the European study on HD burden, a specific tool was created: the Huntington Quality of Life Instrument (H-QoL-I). The aim of this study was to optimize the content and validate the H-QoL-I. After a semistructured interview with patients, caregivers and HD specialists, we conducted a patient focus group. A self-reported questionnaire was then developed in French and Italian. A total of 252 patients were recruited to answer the questionnaire. Face, internal and external validities were examined using a variety of methods. The shortened H-QoL-I that resulted from the successive analyses comprises 11 items, which are divided into three dimensions: motor functioning (four items), psychology (four items) and socializing (three items). These three domains were identified as being essential to cover the full domain of the quality of life for patients affected by HD. The H-QoL-I showed an acceptable reliability (Cronbach's α>0.84). Factor analyses demonstrated satisfactory construct validity. Moreover, the item internal consistency and item discriminant validity criteria were fulfilled. No differential item functioning was detected. External validity supported the scale's robustness. These data support the validity of the H-QoL-I in patients with HD.

Entities:  

Mesh:

Year:  2012        PMID: 22508443     DOI: 10.1097/YIC.0b013e3283534fa9

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  8 in total

Review 1.  A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.

Authors:  Jane S Paulsen; Martha Nance; Ji-In Kim; Noelle E Carlozzi; Peter K Panegyres; Cheryl Erwin; Anita Goh; Elizabeth McCusker; Janet K Williams
Journal:  Prog Neurobiol       Date:  2013-09-11       Impact factor: 11.685

Review 2.  Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.

Authors:  Noelle E Carlozzi; Angela Miciura; Nicholas Migliore; Praveen Dayalu
Journal:  J Huntingtons Dis       Date:  2014

3.  Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease.

Authors:  Nicholas R Boileau; Julie C Stout; Janes S Paulsen; David Cella; Michael K McCormack; Martha A Nance; Samuel Frank; Jin-Shei Lai; Noelle E Carlozzi
Journal:  J Huntingtons Dis       Date:  2017

4.  HD-PRO-TRIAD™ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease.

Authors:  Noelle E Carlozzi; David Victorson; Victor Sung; Jennifer L Beaumont; Wendy Cheng; Brian Gorin; Mei Sheng Duh; David Samuelson; David Tulsky; Sandra Gutierrez; Cindy J Nowinski; Allison Mueller; Vivienne Shen; Samuel Frank
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-04-14

5.  Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives.

Authors:  David Victorson; Noelle E Carlozzi; Samuel Frank; Jennifer L Beaumont; Wendy Cheng; Brian Gorin; Mei Sheng Duh; David Samuelson; David Tulsky; Sandra Gutierrez; Cindy J Nowinski; Allison Mueller; Vivienne Shen; Victor Sung
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-04-14

6.  The quality of life of Spanish patients with Huntington's disease measured with H-QoL-I and EQ-5D.

Authors:  Julie Dorey; Emilie Clay; Amine Khemiri; Anis Belhadj; Patricia Trigo Cubillo; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2016-10-13

7.  Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.

Authors:  Karine Cambon; Virginie Zimmer; Sylvain Martineau; Marie-Claude Gaillard; Margot Jarrige; Aurore Bugi; Jana Miniarikova; Maria Rey; Raymonde Hassig; Noelle Dufour; Gwenaelle Auregan; Philippe Hantraye; Anselme L Perrier; Nicole Déglon
Journal:  Mol Ther Methods Clin Dev       Date:  2017-05-11       Impact factor: 6.698

8.  Domains of Well-Being in Minimally Conscious Patients: Illuminating a Persistent Problem.

Authors:  Mackenzie Graham
Journal:  AJOB Neurosci       Date:  2018-06-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.